Active Pharmaceutical Ingredients
- Industrial Coatings
- Dyes and Pigments
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
- Analytical Chemistry
- Pharmaceutical Intermediates
In 2020, a global outbreak of the new crown epidemic disrupted the business activities of almost all companies, and the drug R&D and production of pharmaceutical companies is no exception.
2021 global CRO ranking TOP10
①This list covers CRO in a broad sense, and its business areas cover preclinical research, clinical trials, pharmaceutical development, and commissioned production of raw materials and drugs (CDMO and CMO) related to new drug research and development;
②The two data of ICON+PRA are directly related Plus;
③Lonza's income is 4.5 billion Swiss francs, and the exchange rate is converted into US dollars at 1.1;
④Catalent's fiscal year is from July 2019 to June 2020;
⑤Wuxi includes Wuxi AppTec and WuXi Biologics, and the combined income is converted to US dollars at an exchange rate of 6.8;
⑥Parexel has been delisted after being acquired by a consortium in 2017.
Judging from the TOP10 list, the top two CRO companies in the world both have revenues of more than US$10 billion, widening a huge gap with the players behind them, and their dominant position is unbreakable.
Syneos is the only company on the list that has shrunk in performance (Parexel is not known), while WuXi is the only Chinese element in the list.
Also benefiting from the new crown virus epidemic are Labcorp and Catalent's testing business and vaccine production business, respectively.
This article gives a brief introduction to the world's TOP10 CRO companies.
The main business of LabCorp is clinical diagnostics.
In 2020, the company's revenue is approaching US$14 billion, an increase of 21% over the previous year.
The company has a large and complete laboratory system not only in North America, but also in the world.
NO.2 IQVIA (Ai Kunwei)
Although in terms of performance and size, IQVIA is slightly lower than Labcorp, but the industry generally believes that IQVIA has a greater influence than Labcorp, and this has to mention the company's predecessor.
In 2016, Quintiles and IMS Health merged to form IQVIA, which became the most important event in the industry that year.
In 2020, the company's revenue was 11.36 billion U.S.dollars, an increase of only 2.% compared to the previous year.
In 2020, IQVIA has 70,000 employees worldwide.
PRA’s revenue in 2020 was US$3.183 billion, an increase of 3.8% over the previous year; while ICON’s revenue in 2020 was US$2.797 billion, a decrease of 0.
In February 2021, ICON announced the acquisition of PRA for US$12 billion.
These two were originally in the global TOP10.
NO.4 Lonza (Lonza)
Lonza is undisputedly the world's largest CDMO company.
The Lonza Group operates two major businesses, of which the Lonza Special Ingredients Business (LSI) focuses on the microbiological control of personal care products, and the volume within the group is relatively small.
In 2020, the company's revenue was 4.5 billion Swiss francs, achieving 12.5% growth.
In response to the new coronavirus epidemic, Lonza used global production capacity to provide a full range of development and production services for Moderna's new coronavirus RNA vaccine (mRNA-1273), with an estimated annual production capacity of 1 billion doses.
PPD, founded in 1985 by Fred Eshelman, Ph.D., had its first IPO in 1996.
It has to be said that PPD has made great moves in China, including the completion of two mergers and acquisitions in China in 2009, the acquisition of Igus and Baonuo, which were of considerable scale in China at that time.Among them, Baonuo founder John V.Oyler founded BeiGene in 2010.
PPD's 2020 revenue is 4.68 billion U.S.dollars, achieving 16.1% growth.
NO.6 Syneos Health
In 2017, INC Research and Inventiv Health merged to form Syneos Health, which once climbed to the third position in the world.
In 2020, the company's revenue was 4.42 billion U.S.dollars.
It is the only company on the list that has suffered negative growth in performance due to the impact of the new crown virus epidemic, and its ranking has also declined.
Although WuXi Biologics and WuXi PharmaTech are two independently-operated listed companies, considering that WuXi Biologics originated from WuXi PharmaTech and the chairman of the two companies is the same person, the two companies are referred to as WuXi PharmaTech.
Department of consolidated calculations.
WuXi's business covers all aspects of new drug research and development, almost all-encompassing and omnipotent, and is already a global giant.
Although it has not yet become the global leader, the influence that everyone feels is undoubtedly insurmountable by its peers.
In 2020, WuXi's consolidated revenue was approximately US$3.26 billion, an increase of 31.4% over 2019.
The number of employees reached 32,000.
Regardless of income or personnel, the growth rate is far ahead of its peers.
And judging from the development trend in recent years, it will still maintain rapid growth.
The negative impact of the new crown virus epidemic on the company is small in scope, mild in severity and short in time.
On the contrary, the epidemic has played a major role in promoting performance to some extent.
On the one hand, the company has undertaken a number of new coronavirus-related R&D and production projects.
On the other hand, the raging overseas epidemic has caused some orders to be transferred to China.